Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Molecular Profiling a Must in Advanced NSCLC

Key clinical point: All patients with metastatic non–small cell lung cancer should be tested for targetable mutations/alterations.

Major finding: The 5-year overall survival for patients with ALK rearrangements now exceeds 40%.

Study details: A review of the literature on medical therapies for non–small cell lung cancer.

Disclosures: The review was supported in part by a grant from the National Cancer Institute to Memorial Sloan Kettering Cancer Center. Dr. Arbour reported serving as a consultant to AstraZeneca and nonfinancial research support from Novartis and Takeda. Dr. Riely reported grants and nonfinancial support from Pfizer, Roche/Genentech/Chugai, Novartis, Merck, and Takeda; a patent pending for an alternate dosing of erlotinib for which he has no right to royalties; and payments from the National Comprehensive Cancer Network to participate in a committee overseeing solicitation and selection of grants to be awarded by AstraZeneca.

Citation:

Arbour KC and Riely GJ. JAMA. 2019;322(8):764-74.